Could a simple mineral improve lung cancer treatment?
NCT ID NCT07149649
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding magnesium to standard chemo-immunotherapy helps people with advanced non-small cell lung cancer. About 230 participants will receive either magnesium or a placebo, as both tablets and infusions. Neither patients nor doctors know who gets what. The goal is to see if magnesium improves survival and is well tolerated.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
magnesium (as Magnesiocard tablets and Magnesium Diasporal IV)
What this could lead to
If it works, this could show that adding magnesium helps standard treatment work better and longer for advanced lung cancer.
What could go wrong
This is an early-to-mid stage trial with only 230 participants. Magnesium may not improve outcomes, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC NSCLC - NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Kantonsspital - St. Gallen
Sankt Gallen, CH-9007, Switzerland
-
Kantonsspital Aarau
Aarau, CH-5001, Switzerland
-
Kantonsspital Baden
Baden, 5404, Switzerland
-
Kantonsspital Graubuenden
Chur, CH-7000, Switzerland
-
Kantonsspital Olten
Olten, 4600, Switzerland
-
Kantonsspital Winterthur
Winterthur, 8401, Switzerland
-
Luzerner Kantonsspital
Lucerne, 6000, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Spital STS AG
Thun, 3600, Switzerland
-
St. Claraspital
Basel, 4058, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Tumorzentrum Aarau - Hirslanden TZA
Aarau, 5001, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Universitätsspital Basel
Basel, 4058, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact